Thompson Siegel & Walmsley’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
Thompson Siegel & Walmsley's XBI Position: Q2 2026 in Review
Thompson Siegel & Walmsley held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 8,000 shares worth $1.27M. The position accounts for 0.02% of the portfolio, ranked #310.
Thompson Siegel & Walmsley first reported a position in XBI in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.3M in Q2 2021. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Thompson Siegel & Walmsley held 8,000 shares of State Street SPDR S&P Biotech ETF worth $1.27M as of Q2 2026.
- Thompson Siegel & Walmsley left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
- State Street SPDR S&P Biotech ETF made up 0.02% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #310 holding.
- Thompson Siegel & Walmsley first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 25 quarters since.
- Thompson Siegel & Walmsley's State Street SPDR S&P Biotech ETF position peaked at $1.3M in Q2 2021.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.